A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.Bold, G., Schnell, C., Furet, P., McSheehy, P., Bruggen, J., Mestan, J., Manley, P.W., Druckes, P., Burglin, M., Durler, U., Loretan, J., Reuter, R., Wartmann, M., Theuer, A., Bauer-Probst, B., Martiny-Baron, G., Allegrini, P., Goepfert, A., Wood, J., Littlewood-Evans, A.
(2016) J.Med.Chem. 59: 132-146
- PubMed: 26629594
- DOI: 10.1021/acs.jmedchem.5b01582
- PubMed Abstract:
- Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
Manley, P.W.,Bold, G.,Bruggen, J.,Fendrich, G.,Furet, P.,Mestan, J.,Schnell, C.,Stolz, B.,Meyer, T.,Meyhack, B.,Stark, W.,Strauss, A.,Wood, J.
(2004) Biochimica et Biophysica Acta, Proteins and Proteomics 1697: 17
This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular as ...
This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular assays, the compounds exhibit single-digit nanomolar potency toward VEGFR2. Compounds of this series show good exposure in rodents when dosed orally. They potently inhibit VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by ELISA for TIE-2 in lysates or by immunohistochemical analysis. This novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role.
Oncology Research, Novartis Institutes for BioMedical Research , 4002 Basel, Switzerland.